Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$69.80 USD

69.80
2,470,028

+0.87 (1.26%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $69.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?

Is (EXAS) Outperforming Other Medical Stocks This Year?

Exact Sciences (EXAS) to Post Q3 Earnings: What's in Store?

During Exact Sciences' (EXAS) third-quarter 2019 conference call, investor focus will be on the volume growth rate of its non-invasive screening test for colorectal cancer, Cologuard.

Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Exact Sciences (EXAS) closed at $96.47, marking a -0.94% move from the previous day.

Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag

Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.

Seattle Genetics Begins Phase III Study on Tucatinib Combo

Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.

bluebird Inks Genome Editing Research Deal With Novo Nordisk

bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.

Seattle Genetics Up More Than 20% in 3 Months: Here's Why

Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.

Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?

Is (EXAS) Outperforming Other Medical Stocks This Year?

Exact Sciences Corporation Enters Oversold Territory

Exact Sciences Corporation has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Exact Sciences Gets FDA Nod for Label Expansion of Cologuard

Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.

Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil

Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil

Tracey Ryniec headshot

Stock Investors: Do You Need a Late Cycle Plan?

The financial media keeps talking about the economy being in the late cycle but that doesn't mean you can't be buying stocks.

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

Tirthankar Chakraborty headshot

3 Cancer Treatment Stocks to Enrich Your Portfolio

Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.43% and 9.86%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Exact Sciences (EXAS) Q2 Earnings Expected to Decline

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer

The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer

Tirthankar Chakraborty headshot

3 Stocks to Win Big in the Fight Against Cancer

We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.

Tracey Ryniec headshot

The 5 Hottest Earnings Charts This Week

These 5 stocks have had big rallies in 2019. Are they too hot to handle?

Earnings Preview: Exact Sciences (EXAS) Q1 Earnings Expected to Decline

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?

During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

Sector ETF report for PTH

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

Tracey Ryniec headshot

NASH, Allergies and Beauty Stocks: Invest or Not?

There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?

Exact Sciences (EXAS) Reports Q4 Loss, Misses Revenue Estimates

Exact Sciences (EXAS) delivered earnings and revenue surprises of 12.00% and -0.01%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?